Diabetic ketoacidosis: Should current management include subcutaneous insulin injections?

  • Rocio Gavidia Quezada Rocio Gavidia Quezada MD, Hawa Edriss MD
  • Hawa Edriss Department of Internal medicine at Texas Tech University Health Sciences Center in Lubbock, TX


Diabetic ketoacidosis is a well-known acute complication in patients with both type 1 andtype 2 diabetes mellitus. Although mortality has decreased considerably, it remains an importantcause for admission to intensive care units. Medical management includes intravenous fluidtherapy, insulin, correction of electrolyte abnormalities, and addressing the precipitating factorwhich in most cases is infection or non-compliance with insulin therapy. Usually patients withdiabetic ketoacidosis are admitted to the intensive care unit for continuous infusion of insulin;however, the development of rapid acting insulin analogues has made it possible to treatmild to moderate diabetic ketoacidosis with subcutaneous insulin. Although studies usingsubcutaneous insulin include only a small number of patients, this approach seems as effectiveas intravenous insulin infusions in patients with mild to moderate diabetic ketoacidosis. Diabeticeducation and close follow-up for patients admitted for diabetic ketoacidosis remain essentialto avoid recurrence and readmissions.Keywords: Diabetic ketoacidosis, acute complication in diabetes, rapid acting insulinanalogues, subcutaneous insulin in diabetic ketoacidosis


Download data is not yet available.

Author Biography

Rocio Gavidia Quezada, Rocio Gavidia Quezada MD, Hawa Edriss MD

Department of Internal medicine at Texas Tech
University Health Sciences Center in Lubbock, TX


Powers AC. Harrison’s Principles of Internal Medicine 17th

edition, Chapter 338, Diabetes Mellitus, Diabetes Ketoacidosis

Pathophysiology, p 2283.

Wang J, Williams DE, Narayan KM, Geiss LS. Declining death

rates from hyperglycemic crisis among adults with diabetes,

US 1985-2002. Diabetes Care 2006 Sep; 29(9):2018-22.

Nyenwe EA, Kitabchi AE. The Evolution of diabetic ketoacidosis:

An update of its etiology, pathogenesis and management.

Division of Endocrinology, Diabetes and Metabolism,

University of Tennessee Health Science Center. https://doi.

org/10.1016/j.metabol.2015.12.007. Published: 2016-04.

Dhatariya K. Diabetic emergencies. Diabetic Ketoacidosis

and Hyperosmolar Crisis in Adults. Medicine; 42 (12):

p723-726. [published online: October 20, 2014].

Munro JF, Cambell IW, McCuish AC et al. Euglycemic diabetic

ketoacidosis. Br. Med J 1973; 2(5866):578–80.

Burge MR, Hardy KJ, Schade DS. Short-term fasting is a

mechanism for the development of euglycemic ketoacidosis

during periods of insulin deficiency. J Clin Endocrinol

Metab 1993; 76(5):1192–8.

Juarez Ramirez Tello E, Orellana-Barrios M, Nugent K.

Sodium-glucose co-transporter 2 inhibitor induced diabetic

ketoacidosis in a type 2 diabetic patient. Amer J Med Sci;

(6): 634-635.

Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic

ketoacidosis: A potential complication of treatment with

sodium–glucose cotransporter 2 inhibition. Diabetes Care

Sep; 38(9): 1687-1693.

Taylor SI, Blau JE, Rother KI. Perspective: SGLT2 inhibitors

may predispose to ketoacidosis. J Clin Endocrinol

Metab 2015 Aug; 100 (8):2849-52.

Hyperglycemic Crises in Diabetes. American Diabetes Association.

Diabetes Care 2004. Jan; 27(Supplement 1): s94-s102.

Bratusch-Marrain PR, Komajati M, Waldhausal W. The

effect of hyperosmolarity on glucose metabolism. Pract Cardiol

; 11:153–63.

Waldhausl W, Kleinberger G, Korn A, et al. Severe hyperglycemia:

effects of rehydration on endocrine derangements

and blood glucose concentration. Diabetes 1979; 28:577–84.

Martin HE, Smith K, Wilson ML. The fluid and electrolyte

therapy of severe diabetic acidosis and ketosis; a study of

twenty-nine episodes (twenty-six patients). Am J Med 1958;


Doshi P, Potter A, De Los Santos D, Banuelos R, Darger

B, Chathampally Y. Prospective randomized trial of insulin

glargine in acute management of diabetic ketoacidosis in the

emergency department: a pilot study. Academic Emergency

Medicine 2015; 22:658–662.

Umpierrez G, Cuervo R, Karabell A, Latif K, Freire A,

Kitabchi A. Treatment of diabetic ketoacidosis with subcutaneous

insulin aspart. Diabetes Care 2004 Aug; 27(8): 1873-


Ersöz HO, Ukinc K, Köse M, et al. Subcutaneous Lispro

and intravenous regular insulin treatments are equally effective

and safe for the treatment of mild and moderate diabetic

ketoacidosis in adult patients. Int J Clin Pract 2006;


Miller DW, Slovis CM. Hypophosphatemia in the emergency

department therapeutics. Am J Emerg Med 2000; 18:457–61.

Duhon B, Attridge RL, Franco-Martinez AC, Maxwell PR,

Hughes DW. Intravenous sodium bicarbonate therapy in

severely acidotic diabetes ketoacidosis. Ann Pharmacother

(7-8):970-5. [Epub 2013 Jun 4].

American Diabetes Association. Diabetes Care in the Hospital,

Insulin therapy, transitioning to subcutaneous insulin

Jan; 40(Supplement 1): S120-S127. https://doi.


Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy

in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:

– 840.

How to Cite
Gavidia Quezada, R., & Edriss, H. (2017). Diabetic ketoacidosis: Should current management include subcutaneous insulin injections?. The Southwest Respiratory and Critical Care Chronicles, 5(19), 6-10. https://doi.org/10.12746/swrccc.v5i19.389